Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug comprising aripiprazole and cilostazol

A technology of aripiprazole and cilostazol, applied in the field of combination of aripiprazole and cilostazol, can solve problems such as mental changes, showing mental changes and the like

Inactive Publication Date: 2018-08-21
OTSUKA PHARM CO LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is known that even when a patient with a disease caused by a vascular disorder is properly treated and sees improvement, the patient may exhibit or be at potential risk of exhibiting mental changes at a later stage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug comprising aripiprazole and cilostazol
  • Drug comprising aripiprazole and cilostazol
  • Drug comprising aripiprazole and cilostazol

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0160] 1.1: In vivo test (medium cerebral artery occlusion model)

[0161] In this experiment, 30 male 10-week-old C57BL / 6J mice were divided into the following groups. To each group, 6 mice were assigned.

[0162] Grouping

[0163] 1) Control group

[0164] 2) Vehicle giving group

[0165] 3) Cilostazol administration group alone

[0166] 4) Aripiprazole alone administration group

[0167] 5) Cilostazol and Aripiprazole administration group

[0168] A 20% DMSO aqueous solution was used as the vehicle. The dose of cilostazol and aripiprazole were 3 mg / kg each. For the cilostazol and aripiprazole groups, the dose of cilostazol and aripiprazole were also 3 mg / kg each. Each drug was dissolved in 20% DMSO aqueous solution and administered to mice.

[0169] Test schedule

[0170] All mice were given a 14-day adaptation period. On the day after the last day of the adaptation period, 4 groups of mice other than the control group were subjected to the operation described later to induce midd...

example 2

[0206] 2.1: In vitro testing

[0207] To evaluate the effects of aripiprazole and / or cilostazol on neuronal cells. Specifically, the expression level of heme oxygenase-1 ("HO-1") was measured using Western blotting. HO-1 is a neuroprotective protein that protects cells from damage caused by oxidative stress.

[0208] HT22 neuronal cells (a neuronal cell line derived from the mouse hippocampus) in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 units / mL penicillin, and 100 μg / mL streptomycin (DMEM). Thereafter, the cultured cells were divided into the following 4 groups: [1] untreated group, [2] group treated with aripiprazole (1 μM), [3] group treated with cilostazol (1 μM), and [ 4] A group treated with aripiprazole (1 μM) + cilostazol (1 μM), and the separated cells were treated separately. Each treatment was performed by exposing the cell group to each substance for 6 hours. After that, the treated cells were collected and lysed in a lysis buffer ...

example 3

[0215] 3.1: In vivo test (bilateral carotid artery stenosis model)

[0216] A mouse model with bilateral common carotid artery stenosis was prepared, and the Morris water maze test was performed on the mouse model to evaluate spatial learning and memory capabilities. Forty male 10-week-old C57BL / 6J mice (purchased from Koatech, Seoul, Korea) were divided into the following groups and used. To each group, 8 mice were assigned.

[0217] Grouping

[0218] 1) Control group

[0219] 2) Vehicle giving group

[0220] 3) Aripiprazole alone administration group

[0221] 4) Cilostazol alone administration group

[0222] 5) Cilostazol and Aripiprazole administration group

[0223] A 25% DMSO aqueous solution was used as the vehicle. Also for the cilostazol and aripiprazole administration groups, the dose of aripiprazole is 0.5 mg / kg, and the dose of cilostazol is 20 mg / kg. Each drug was dissolved in 25% DMSO aqueous solution and orally administered to mice.

[0224] Test schedule

[0225] Give a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention enables treatment and / or prevention of dementia, cognitive impairment, and vascular depression by a combination of aripiprazole and cilostazol, or the like. The combination contains aripiprazole and cilostazol, and is used for the treatment and / or prevention of at least one member selected from the group consisting of dementia, cognitive impairment, and vascular depression.

Description

Technical field [0001] The present invention relates to a medicament of aripiprazole and cilostazol, and specifically relates to a combination of aripiprazole and cilostazol for the treatment and / or prevention of dementia, cognitive impairment, and / or vascular depression . Background technique [0002] With the rapid aging of society, dementia and cognitive impairment have attracted more and more attention. Diseases caused by vascular diseases (such as stroke and cerebral infarction) caused by vascular aging have become more and more serious problems, especially in the elderly. It is known that even if a patient suffering from a disease caused by a vascular disorder is given proper treatment and sees improvement, the patient may still show mental changes or have a potential risk of showing mental changes at a later stage. For example, it is known that vascular depression that develops after treatment of vascular disorders is becoming an increasingly serious problem (see, for ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61K31/4709A61P9/10A61P25/14A61P25/16A61P25/24A61P25/28
CPCA61K31/4709A61K31/496A61P25/28A61P25/24A61P25/00A61K2300/00
Inventor 辛花镜崔秉泰洪起焕
Owner OTSUKA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com